Repetto Gabriela M, Guzmán M Luisa, Delgado Iris, Loyola Hugo, Palomares Mirta, Lay-Son Guillermo, Vial Cecilia, Benavides Felipe, Espinoza Karena, Alvarez Patricia
Facultad de Medicina, Center for Genetics and Genomics, Clinica Alemana Universidad del Desarrollo, Santiago, Chile Hospital Padre Hurtado, Santiago, Chile.
Facultad de Medicina, Center for Genetics and Genomics, Clinica Alemana Universidad del Desarrollo, Santiago, Chile.
BMJ Open. 2014 Nov 6;4(11):e005041. doi: 10.1136/bmjopen-2014-005041.
Chromosome 22q11.2 deletion is the most commonly occurring known microdeletion syndrome. Deaths related to the syndrome have been reported, but the magnitude of death has not been quantified. This study evaluated the deletion's impact on survival and its clinical manifestations in a large cohort of Chilean patients.
Demographic and clinical data of individuals with 22q11 deletions diagnosed between 1998 and 2013 were collected from medical records and death certificates. Case fatality rate was calculated and compared with national vital statistics. OR with 95% CI analysis was used to assess the association between clinical manifestations and death.
Genetic services in tertiary care centres in Chile, following patients with 22q11.2 deletion.
Fatality rate and associated factors.
59 of 419 patients (14.1%) died during the study period at a median of 3.4 months (range 0 to 32 years of age). Factors associated with death included congenital heart disease (OR 5.27; 95% CI 2.06 to 13.99; p<0.0001), hypocalcaemia (OR 4.27; 95% CI 1.67 to 11.15; p<0.002) and airway malacia (OR 13.37; 95% CI 1.19 to 110.51; p<0.002). Patients with deletions and defects such as tetralogy of Fallot with or without pulmonary atraesia, truncus arteriosus or ventricular septal defect, had a 2.6-fold to 4.6-fold higher death rate compared with nationwide reports for the same types of defects.
In this cohort, we observed a death rate of 14.1%, implying that one in seven patients with 22q11 deletion died during the study period. Significant associations with cardiac defects, hypocalcaemia and airway malacia were observed. Furthermore, the death risk in patients with 22q11 deletion and cardiac defects exceeded the global figures observed in Chile for infants with structurally similar but apparently isolated anomalies. These observations indicate a need to identify patients who may require specific perioperative management to improve survival.
22q11.2染色体缺失是最常见的已知微缺失综合征。已有与该综合征相关的死亡报告,但死亡规模尚未量化。本研究评估了该缺失对一大群智利患者生存的影响及其临床表现。
收集1998年至2013年间诊断为22q11缺失的个体的人口统计学和临床数据,数据来源于病历和死亡证明。计算病死率并与国家生命统计数据进行比较。采用比值比(OR)及95%可信区间(CI)分析来评估临床表现与死亡之间的关联。
智利三级医疗中心的遗传服务机构,对22q11.2缺失患者进行随访。
病死率及相关因素。
在研究期间,419例患者中有59例(14.1%)死亡,中位年龄为3.4个月(范围为0至32岁)。与死亡相关的因素包括先天性心脏病(OR 5.27;95%CI 2.06至13.99;p<0.0001)、低钙血症(OR 4.27;95%CI 1.67至11.15;p<0.0 * )和气道软化(OR 13.37;95%CI 1.19至110.51;p<0.002)。与法洛四联症伴或不伴肺动脉闭锁、动脉干或室间隔缺损等缺失和缺陷相关的患者,其死亡率比全国范围内相同类型缺陷的报告高出2.6倍至4.6倍。
在该队列中,我们观察到病死率为14.1%,这意味着在研究期间,每七名22q11缺失患者中就有一名死亡。观察到与心脏缺陷、低钙血症和气道软化有显著关联。此外,22q11缺失且有心脏缺陷患者的死亡风险超过了智利观察到的全球范围内结构相似但明显孤立异常的婴儿的数字。这些观察结果表明,需要识别可能需要特定围手术期管理以提高生存率的患者。